Synthetic Biologics Inc. announced Isaac J. Bright, MD, has joined the company in the new position of Vice President, Corporate Development. Dr. Bright will be responsible for strategic business and corporate development activities to help maximize potential partnering opportunities for the company's two lead GI microbiome-focused drug candidates: SYN-010, designed to reduce methane production in the gut to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, designed to prevent C. difficile infection (CDI), antibiotic associated diarrhea (AAD) and the emergence of antibiotic resistant organisms. Dr. Bright is a life sciences and healthcare industry veteran with 15 years of transactional and operational experience. Most recently, he led the U.S. private equity investment practice as a Partner at Merieux Development where he was responsible for investment thesis development, company screening and comprehensive due diligence for the healthcare and venture capital fund.